Medindia
Medindia LOGIN REGISTER
Advertisement

Pathwork Diagnostics Announces Key Additions to Management Team

Thursday, October 9, 2008 General News
Advertisement
SUNNYVALE, Calif., Oct. 8 Pathwork Diagnostics, amolecular diagnostics company focused on oncology, announced today theappointment of two key positions within the company's management team,Fletcher Payne as Chief Financial Officer and Mark McDonough as Vice Presidentof US Sales. These professionals bring over 20 years of industry expertise intheir respective positions to Pathwork.
Advertisement

"Having Fletcher and Mark on the Pathwork management team will be a greatasset moving forward," said Deborah J. Neff, President and Chief ExecutiveOfficer of Pathwork Diagnostics. "Both have proven track records in helpingemerging companies grow efficiently and achieve results."
Advertisement

Pathwork's new CFO, Fletcher Payne, a graduate of UC Berkeley's HaasSchool of Business with a BS in Business Administration, joins Pathwork fromPlexxikon Inc., a biopharmaceutical company where he served as a VP and CFO.Payne will lead the financial team, implement processes to support commercialgrowth and develop the overall financial strategy. Payne has over 20 years ofbusiness and financial experience, in both start-up and Fortune 500 companies.Prior to Plexxikon, he worked for Rinat Neuroscience, Dynavax Technologies,Cell Genesys, Sun Microsystems and IBM.

Mark McDonough joins Pathwork as Vice President of US Sales from US LABS,a division of Laboratory Corporation of America. With over 10 years of cancerdiagnostics and reference laboratory experience, Mark will be responsible forthe strategic and tactical sales initiatives at Pathwork. Prior to his time atUS LABS, McDonough held various sales and sales management roles at VentanaMedical Systems and served as a Navigator and Communications Officer in theUnited States Navy. McDonough is a graduate of Miami University of Ohio with aBS in Finance.

About Pathwork Diagnostics

Pathwork Diagnostics, Inc., based in Sunnyvale, Calif., develops andcommercializes high-value molecular diagnostics for oncology. The company'sfirst test to market -- the Pathwork(R) Tissue of Origin Test -- utilizesproprietary analytics and a companion Pathchip(R) microarray, which runs onthe proven Affymetrix GeneChip(R) System. The test aids in determining ahard-to-identify tumor's origin so that standard-of-care, cancer-specifictreatment can begin. The test is FDA-cleared as an in vitro diagnostic kit,while a functionally equivalent version of the test is also available throughthe CLIA-certified Pathwork(R) Diagnostics Laboratory. For more information,call 1.877.808.0006 or visit http://www.pathworkdx.com.

Pathwork, Pathchip, Pathwork Diagnostics, and the Pathwork Diagnosticslogo are trademarks or registered trademarks of Pathwork Diagnostics, Inc.Other names may be the trademarks of their respective owners.

SOURCE Pathwork Diagnostics, Inc.
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close